Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...